Introduction
Von Willebrand factor (vWF) is a large, multimeric plasma glycoprotein, synthesized in vascular endothelial cells and megakaryocytes, which plays a central role in haemostasis. It functions not only as a carrier protein for coagulation factor VIII but also has a crucial role in mediating the shear-ratedependent adhesion and aggregation of platelets at sites of injury.' A qualitative and/or quantitative deficiency ofvon Willebrand factor, as is the case in patients with congenital von Willebrand disease, may likewise result in a bleeding tendency. Apart from congential von Willebrand disease, acquired cases ofvon Willebrand disease (AvWD) have been described.2'3 They usually occur in association with monoclonal gammopathies of undetermined significance or lymphoproliferative disorders, suggesting that the acquired deficiency of von Willebrand factor has an immunological basis,2'3 although AvWD occasionally has been described in association with solid tumours4'5 or hypothyroidism. 6 Two major mechanisms have been proposed to explain the acquired deficiency of von Willebrand factor in patients with lymphoproliferative disorders or monoclonal gammopathies of undetermined significance. Firstly, antibodies inactivate functional or immunological sites of vWF or form a complex, inducing a rapid clearance from the circulation.2'3 Secondly, the plasma deficiency of vWF results from selective absorption of vWF to malignant cells. [2] [3] [4] The treatment of AvWD is initially directed toward treatment of the primary illness as AvWD may resolve when a remission of the underlying disorder has been achieved.4-6 However, treatment of the underlying disorder may not always be possible or requires surgery, which poses a challenge to an already deteriorated haemostatic system. Adequate haemostasis in AvWD may be achieved with the infusion of factor VIII/vWF concentrates or with the administration of desmopressin. 7 We report a case ofAvWD with severe postoperative bleedings, unsatisfactorily responding to classical vWF replacement therapy but successfully treated with high-dose intravenous gammaglobulins (IV:Ig). This new treatment mode of AvWD is discussed in view of a critical analysis of the available literature. A re-evaluation of the monoclonal gammopathy in August 1993 revealed a progression of the monoclonal paraprotein to a multiple myeloma (a monoclonal cytoplasmic IgG K-positive plasma cell population, compromising 34% of the bone marrow cells; osteolytic lesions of the skull; total serum IgG 14.6 g/l). In October 1993 she presented with postmenopausal blood loss. Laboratory tests revealed an Ivy bleeding time> 15 minutes, FVIII:C 0.87 U/ml, vWF:Ag 0.38 U/ml, vWF: RCF 0.11 U/ml, collagen binding activity (vWF: CBA) 0.05 U/ml (normal range for all vWF-related parameters 0.60-1.40 U/ml) and an abnormal multimeric pattern of vWF. A diagnostic curettage under coverage of a factor VIII/vWF concentrate (Haemate PT, Behring, Germany) revealed atypical endometrial hyperplasia with focal suspicion on adenocarcinoma. The preventative administration of desmopressin was contraindicated in this patient because of hypertension. A subsequent total abdominal hysterectomy and right oophorectomy (pathologic examination of the uterus revealed no malignancy) was complicated by postoperative bleeding despite preventive infusions of Haemate PM. Adequate haemostasis could be obtained with Haemate pTM but required frequent infusions and high dosages (up to 4,000 IU every 2 hours) due to a functional inactivation and rapid clearance of infused vWF. We therefore instituted an alternative but empirical treatment with high-dose (1 g/kg bodyweight) intravenous gammaglobulin (Central Laboratory for the Blood Transfusion Services, Amsterdam), which is devoid of any vWF activity, for 3 consecutive days. contrast, infusion of high-dose gammaglobulins induced a long-term rise of vWF-related activities and normalization of Ivy BT (Figure 2 ). The FVIII:C, vWF:Ag, vWF:RCF, and vWF:CBA peaked on the sixth day after institution ofgammaglobulin therapy at > 4.00 U/ml, > 4.00 U/ml, 4.62 U/ml and > 4.00 U/ml, respectively. From day 6 all vWF-related activities slowly declined in two weeks to the clearly deficient values observed on admission. During this interval bleeding did not recur. The high preinfusion values for all vWFrelated parameters are caused by frequent dosages of Haemate pTM to secure haemostasis on the day prior to the administration of high-dose intravenous gammaglobulins.
Discussion
The patient presented illustrates the beneficial effect of high-dose intravenous gammaglobulin in the management of bleeding episodes in AvWD, insufficiently responding to infusions of a factor VIII/vWF concentrate. It is unlikely that the beneficial and long-lasting effect of high-dose gammaglobulin therapy on vWF-related activities are caused by the infusion of factor VIII/vWF concentrates on the day prior to institution of gammaglobulin therapy given the decreased halflife time of 1-2 hours of infused vWF in this patient (the normal half-life time of infused vWF is 8-12 hours7). Although in vitro mixing experiments of patient's plasma with normal pooled plasma, in order to demonstrate an inhibitor directed to factor VIII or vWF, did not reveal significant inactivation of the vWF-related activities, the decreased half-life time of infused vWF in vivo is very suggestive for the presence of a circulating anti-vWF inhibitor. This inhibitor probably forms a complex with plasma von Willebrand factor with inactivating functional sites on vWF in vivo and inducing a rapid clearance of these vWF-inhibitor complexes from the circulation by the mononuclear phagocytic systems.
Using CD-ROM assisted search ofthe published literature of 1988-1993, 10 additional AvWD patients (two females, eight males; ranging in age from 42 to 82 years), summarized in Table I , were identified in whom high-dose intravenous gammaglobulin therapy was successful.8"16 All patients had a monoclonal paraprotein or lymphoproliferative disorder as underlying disease, which emphasizes the presumed immunological aetiology of the acquired von Willebrand factor deficiency. An in vitro demonstrable inhibitor directed to vWF as a possible explanation for the acquired coagula- Unfortunately, high-dose intravenous gammaglobulin therapy is not always effective in AvWD. It has occasionally been reported that patients with AvWD develop resistance toward IV:Ig therapy after repeated courses of high-dose intravenous gammaglobulin therapy.8 Furthermcre, we have recently observed a primary resistance toward IV:Ig therapy in a 63 year old male patient with a chronic lymphocytic leukaemia and associated AvWD (unpublished observation). In these cases of AvWD, both refractory to classical vWF replacement therapy and high-dose intravenous gammaglobulin therapy intensive plasma exchange'8 or even extracorporeal immunoabsorption of anti-vWF antibodies'9 may be considered to induce a temporary improvement of the coagulation defect at times of bleeding.
In conclusion, an empirical treatment with highdose intravenous gammaglobulin therapy should be considered in each patient with AvWD, refractory to classical cWF replacement therapy, to induce a long-term improvement of the coagulation defect.
